CellProthera will participate in the Global CardioVascular Clinical Trialists Forum (CVCT) on November 30 – December 2nd,...

Kim Smith, a 66-year-old heart attack patient, experienced a life-changing breaktrough after receiving stem cell therapy at...

Final patient receives ProtheraCytes(R) cell therapy to regenerate damaged heart tissue following severe heart attack. Study remains...

Final patient receives ProtheraCytes® cell therapy to regenerate damaged heart tissue following severe heart attack Study remains...

DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about...

Peter Altman, CEO of BioCardia, and Matthieu de Kalbermatten, CEO of CellProthera, comment on trans-endocardial intramyocardial delivery...

“Cell-based therapies have the potential to regenerate heart tissue as an alternative to heart transplante. Here, Dr...

“Autologous cell therapies are made from living cells, harvested from specific people. Every batch of inputs is...

” BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction...

“Through its Phase I/IIb EXCELLENT clinical trial, CellProthera, a France-based biotechnology research company focusing on cardiac tissue...

Investment landscape In 2023, Matthieu de Kalbermatten, CEO of CellProthera, looks forward to presenting the final safety...

Posted in DDW Exclusive Content, Market Reports | Tagged Advanced Therapy Medicinal Products (ATMPs), Alliance for Regenerative...